Formulation: A lyophilized powder
Formal Name: (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl-(2E,4E)-2,4-octadienoic acid ester
Purity: ≥98%
Formula Markup: C47H68O17
Formula Weight: 905
Shelf life (days): 1460
CAS Number: 83314-01-6
Notes: Bryostatin 1 is a marine macrolide that has been found in B. neritina and has diverse biological activities.{67064},{67065},{67066},{67067},{67068} It binds to PKCα, PKCβ1, PKCγ, PKCδ, PKCε, PKCη, and PKCθ (Kis = 0.8-3.0 nM) and induces PKC activation or inhibition in cancer cells in a concentration-dependent manner.{67064},{67065} Bryostatin 1 (50 nM) reduces the production of IL-2 and increases the production of IL-10 in LPS-stimulated mouse bone marrow-derived dendritic cells (BMDCs).{67064} It decreases cell surface levels of CD4 and chemokine (C-C motif) receptor 5 (CCR5) and reduces HIV-1 infectivity in isolated human monocyte-derived macrophages.{67066} In vivo, bryostatin 1 (30 µg/kg) reduces spinal cord and brain T cell infiltration and disease severity in a mouse model of experimental autoimmune encephalomyelitis (EAE).{67067} It also decreases blast-induced increases in blood-brain barrier (BBB) permeability in a rat model of traumatic brain injury (TBI) when administered at a dose of 2.5 mg/kg.{67068}
English
Deutsch
